Browse

Though it's no longer unusual for a startup to emerge with an investigational drug from China, an immunology biotech is adding that asset to two immune-resetting drugs it already discovered in-hous…

Eli Lilly announced it has paid $2 billion up front as part of its ongoing strategy to acquire vaccine‑focused biotechnology companies, a portion of a larger deal that could total up to $3.8 billio…